EMA Authorised: Osqay (denosumab) — Theramex Ireland Limited

View source ↗

Summary

EMA has authorised Osqay (denosumab) by Theramex Ireland Limited for a bone resorption indication, marking approval in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis Postmenopausal

Drugs mentioned

• Osqay (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption. MAH: Theramex Ireland Limited. Decision date: 08/01/2026